A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Palbociclib (Primary) ; Capecitabine; Epirubicin; Exemestane; Fulvestrant; Letrozole; Paclitaxel; Tamoxifen; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PADMA
- 30 Sep 2024 Status changed from recruiting to completed.
- 27 Sep 2024 This study has been completed in Germany, according to European Clinical Trials Database
- 11 Feb 2021 Planned number of patients changed from 260 to 150.